<< Back to News

System Formulary Update
Ublituximab-xiiy (Briumvi)

Situation

Ublituximab-xiiy (Briumvi) 25 mg/mL intravenous solution was approved for addition to the health system formulary at the System Pharmacy and Therapeutics Committee meeting. 

Background

The following medication was reviewed: Ublituximab-xiiy (Briumvi) 25 mg/mL intravenous solution

Assessment/Recommendations

System P&T voted to include the following products on the UNC Health Medication Formulary with RESTRICTION to outpatient/clinic use only:

• Ublituximab-xiiy (Briumvi) 25 mg/mL intravenous solution

Note: Stock of this formulary product may vary at individual entities

Formulary/Epic changes will Go-Live on Tuesday, June 13, 2023.